Product Pathways - Jak/Stat Pathway
PIAS4 (D2F12) Rabbit mAb #4392
|4392S||100 µl (10 western blots)||---||In Stock||---|
|4392||carrier free and custom formulation / quantity||email request|
|W||1:1000||Human, Rat, Monkey||Endogenous||75||Rabbit IgG|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting
Species predicted to react based on 100% sequence homology: Mouse.
Specificity / Sensitivity
PIAS4 (D2F12) Rabbit mAb detects endogenous levels of total PIAS4 protein.
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Lys59 of human PIAS4 protein.
The protein inhibitor of activated Stat (PIAS) proteins, which include PIAS1, PIAS3, PIASx, and PIASy, were originally characterized based on their interaction with the Stat family of transcription factors (1,2). PIAS1, PIAS3, and PIASx interact with and repress Stat1, Stat3, and Stat4, respectively (1-3). Deletion of PIAS1 leads to inhibition of interferon-inducible genes and increased protection against infection (4). The PIAS family contains a conserved RING domain that has been linked to a function as a small ubiquitin-related modifier (SUMO) ligase, coupling the SUMO conjugating enzyme Ubc9 with its substrate proteins (5,6). Numerous studies have now shown that PIAS family members can regulate the activity of transcription factors through distinct mechanisms, including NF-κB (7,8), c-Jun, p53 (5,9), Oct-4 (10), and Smads (11,12). The activity of PIAS1 is regulated by both phosphorylation and arginine methylation. Inflammatory stimuli can induce IKK-mediated phosphorylation of PIAS1 at Ser90, which is required for its activity (13). In addition, PRMT1 induces arginine methylation of PIAS1 at Arg303 following interferon treatment and is associated with its repressive activity on Stat1 (14).
PIAS4, also known as PIASy, is a specific SUMO-E3 ligase for Ets-1 and represses Ets-1 dependent transcription (15). PIAS4 also alters the nuclear localization, reduces the transcriptional activity of C/EBPδ, and enhances cell proliferation and migration (16).
- Liu, B. et al. (1998) Proc Natl Acad Sci USA 95, 10626-31.
- Chung, C.D. et al. (1997) Science 278, 1803-5.
- Arora, T. et al. (2003) J Biol Chem 278, 21327-30.
- Liu, B. et al. (2004) Nat Immunol 5, 891-8.
- Schmidt, D. and Müller, S. (2002) Proc Natl Acad Sci USA 99, 2872-7.
- Kotaja, N. et al. (2002) Mol Cell Biol 22, 5222-34.
- Liu, B. et al. (2005) Mol Cell Biol 25, 1113-23.
- Tahk, S. et al. (2007) Proc Natl Acad Sci USA 104, 11643-8.
- Bischof, O. et al. (2006) Mol Cell 22, 783-94.
- Tolkunova, E. et al. (2007) J Mol Biol 374, 1200-12.
- Long, J. et al. (2004) Proc Natl Acad Sci USA 101, 99-104.
- Murdoch, R.N. and Edwards, T. (1992) Biochem Int 28, 1029-37.
- Liu, B. et al. (2007) Cell 129, 903-14.
- Weber, S. et al. (2009) Genes Dev 23, 118-32.
- Nishida, T. et al. (2007) Biochem J 405, 481-8.
- Zhou, S. et al. (2008) J Biol Chem 283, 20137-48.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.